Meta-analysis · people
Retatrutide: top odds of 15% or more weight loss across 19 trials
Checked against the paper Meta-analysisPublished by PepVault
The takeaway
In this pooled look at 19 trials, retatrutide led on reaching large weight loss but came with the highest side-effect risk of the drugs compared.
- Kind
- Meta-analysis
- Studied in
- People
- Number studied
- 29506
- Published
- 2025
- Journal
- Obesity (Silver Spring)
What they tested
The team set out to compare how well, and how safely, GLP-1 drugs, dual agonists and retatrutide help adults with overweight or obesity lose weight.
How the study was done
A systematic review and Bayesian network meta-analysis, a method that pools and ranks results from many trials, of 19 randomized controlled trials in 29,506 adults with a BMI of 25 kg/m2 or more. It compared liraglutide, semaglutide, survodutide, tirzepatide, retatrutide and placebo on outcomes measured at 36 weeks or later.

Model. Individual results vary.
What they found
Retatrutide and the dual agonists each reached an average weight change of -11.0 kg, ahead of the GLP-1 drugs at -9.0 kg. For reaching 15% or more weight loss, retatrutide had an odds ratio (a measure of how much more likely an outcome is) of 54.6, followed by dual agonists at 16.4 and GLP-1 drugs at 9.0. Retatrutide also carried the highest risk of side effects. Having type 2 diabetes cut weight loss by 4.338 kg with GLP-1 drugs and by 5.016 kg with dual agonists, while groups with more women or a higher BMI did better.
What it doesn’t show
This study pooled 19 earlier trials rather than running a new one, and it grouped GLP-1 drugs and dual agonists into classes. It covers only adults with a BMI of 25 kg/m2 or more, with outcomes at 36 weeks or later.
The paper
Sinha and Ghosal Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA. Obesity (Silver Spring). 2025.
The compound
More studies on Retatrutide
- Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trialsRandomized trial · people · 2026
- Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1Randomized trial · people · 2026
- Retatrutide: 26.1% fat mass loss at 36 weeks in type 2 diabetesRandomized trial · people · 2025
- Retatrutide: up to 82.4% less liver fat at 24 weeks in MASLD trialRandomized trial · people · 2024
- Retatrutide: 24.2% weight loss at 48 weeks in the 12 mg armRandomized trial · people · 2023
- Retatrutide: up to 8.96 kg placebo-adjusted weight loss in 12 weeksRandomized trial · people · 2022
- Every study on Retatrutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.